Amplia signs Collaboration and Supply Agreement with Lilly
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The agreement includes a clinical trial that aims to assess the safety and efficacy of this combination therapy as a second-line treatment for advanced stage patients. This collaboration expands the clinical application of narmafotinib beyond pancreatic and ovarian cancers, enhancing Amplia's market opportunities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
In the deck
Earlier from Amplia Therapeutics
- Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
- Scientific Paper Studies of narmafotinib - Pancreatic Cancer
- Quarterly Activities/Appendix 4C Cash Flow Report
- Notice of Annual General Meeting/Proxy Form
- Amplia Announces Publication of New FAK Inhibitor Patent Application
Later from Amplia Therapeutics
- Bioshares Biotech Summit Presentation
- CEO Managing Director Presentation to Annual General Meeting
- Results of Annual General Meeting
- Notification regarding unquoted securities - ATX
- Amplia and ANZGOG Finalise Protocol for Ovarian Cancer Trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics